Dacomitinib/Dozerun belongs to the first generation of targeted drugs for lung cancer

Dacomitinib/Dacomitinib (Dacomitinib) is an oral small molecule EGFR tyrosine kinase inhibitor (EGFR-TKI) developed by Pfizer. It is classified as a second-generation targeted drug for lung cancer. Compared with first-generation EGFR-TKIs (such as gefitinib and erlotinib), dacomitinib has the characteristics of irreversibly binding to EGFR, can inhibit the activation of the EGFR signaling pathway more permanently, and has inhibitory effects on multiple subtypes of the HER family. This mechanism of action makes it demonstrate unique clinical value in the treatment of EGFR mutant non-small cell lung cancer (NSCLC).

The characteristic of second-generation EGFR-targeted drugs is that they are often more effective in overcoming part of the resistance mechanism, especially in patients who may still relapse or develop resistance after using first-generation EGFR inhibitors. Dacomitinib provides a new treatment option. Its molecular design makes the drug bind more firmly to the receptor, thereby reducing abnormal activation of signaling pathways. In addition, compared with traditional chemotherapy, targeted drugs are more selective and have relatively more controllable side effects, allowing patients to achieve a better quality of life on the basis of oral drugs.

From a global application perspective, dacomitinib has been approved by the U.S. FDA and the China State Food and Drug Administration for the treatment of patients with locally advanced or metastatic non-small cell lung cancer carrying EGFR sensitive mutations. In China, the incidence of lung cancer, especially EGFR mutant lung cancer, is high. The launch of dacomitinib further expands the clinical treatment toolbox. Although the current third-generation EGFR-TKI (such as osimertinib) has become the first choice in cases of partial resistance, the second-generation dacomitinib is still widely used because of its broad spectrum of action and durability.

In summary, dacomitinib is a second-generation EGFR-targeted drug. Its clinical effect is mainly reflected in inhibiting the multi-target activity of the EGFR family, thereby delaying disease progression and improving patient survival benefits. This positioning not only makes it of clear clinical value, but also provides important inspiration for the subsequent development of targeted drugs.

Reference materials:https://www.pfizer.com/products/product-detail/vizimpro